Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2021 Jan 12

PMID 33431509

Citations 42

Authors

Ilke Tunali

Robert J Gillies

Matthew B Schabath

Affiliations

Soon will be listed here.

Abstract

Medical imaging is the standard-of-care for early detection, diagnosis, treatment planning, monitoring, and image-guided interventions of lung cancer patients. Most medical images are stored digitally in a standardized Digital Imaging and Communications in Medicine format that can be readily accessed and used for qualitative and quantitative analysis. Over the several last decades, medical images have been shown to contain complementary and interchangeable data orthogonal to other sources such as pathology, hematology, genomics, and/or proteomics. As such, "radiomics" has emerged as a field of research that involves the process of converting standard-of-care images into quantitative image-based data that can be merged with other data sources and subsequently analyzed using conventional biostatistics or artificial intelligence (AI) methods. As radiomic features capture biological and pathophysiological information, these quantitative radiomic features have shown to provide rapid and accurate noninvasive biomarkers for lung cancer risk prediction, diagnostics, prognosis, treatment response monitoring, and tumor biology. In this review, radiomics and emerging AI methods in lung cancer research are highlighted and discussed including advantages, challenges, and pitfalls.

Citing Articles

AI-driven biomarker discovery: enhancing precision in cancer diagnosis and prognosis.

Alum E Discov Oncol. 2025; 16(1):313.

PMID: 40082367 PMC: 11906928. DOI: 10.1007/s12672-025-02064-7.

A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.

Kotoulas S, Spyratos D, Porpodis K, Domvri K, Boutou A, Kaimakamis E Cancers (Basel). 2025; 17(5).

PMID: 40075729 PMC: 11898928. DOI: 10.3390/cancers17050882.

Multi-omics model is an effective means to diagnose benign and malignant pulmonary nodules.

Zhang Y, Zhang F, Shen C, Qiao G, Wang C, Jin F Clinics (Sao Paulo). 2025; 80:100599.

PMID: 39985828 PMC: 11904511. DOI: 10.1016/j.clinsp.2025.100599.

Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data.

Zhou L, Mao C, Fu T, Ding X, Bertolaccini L, Liu A Transl Lung Cancer Res. 2025; 13(12):3642-3656.

PMID: 39830777 PMC: 11736583. DOI: 10.21037/tlcr-24-982.

Automatic segmentation model and machine learning model grounded in ultrasound radiomics for distinguishing between low malignant risk and intermediate-high malignant risk of adnexal masses.

Liu L, Cai W, Zheng F, Tian H, Li Y, Wang T Insights Imaging. 2025; 16(1):14.

PMID: 39804536 PMC: 11729609. DOI: 10.1186/s13244-024-01874-7.

References

Liu Y, Balagurunathan Y, Atwater T, Antic S, Li Q, Walker R . Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res. 2016; 23(6):1442-1449. PMC: 5527551. DOI: 10.1158/1078-0432.CCR-15-3102. View

Cook G, OBrien M, Siddique M, Chicklore S, Loi H, Sharma B . Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis. Radiology. 2015; 276(3):883-93. DOI: 10.1148/radiol.2015141309. View

Pao W, Girard N . New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011; 12(2):175-80. DOI: 10.1016/S1470-2045(10)70087-5. View

Wei L, Yang Y, Nishikawa R, Jiang Y . A study on several machine-learning methods for classification of malignant and benign clustered microcalcifications. IEEE Trans Med Imaging. 2005; 24(3):371-80. DOI: 10.1109/tmi.2004.842457. View

Balagurunathan Y, Kumar V, Gu Y, Kim J, Wang H, Liu Y . Test-retest reproducibility analysis of lung CT image features. J Digit Imaging. 2014; 27(6):805-23. PMC: 4391075. DOI: 10.1007/s10278-014-9716-x. View

Hadjiiski L, Sahiner B, Chan H, Petrick N, Helvie M . Classification of malignant and benign masses based on hybrid ART2LDA approach. IEEE Trans Med Imaging. 2000; 18(12):1178-87. DOI: 10.1109/42.819327. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Huang Y, Liu Z, He L, Chen X, Pan D, Ma Z . Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016; 281(3):947-957. DOI: 10.1148/radiol.2016152234. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

10.

Huynh E, Coroller T, Narayan V, Agrawal V, Romano J, Franco I . Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRT. PLoS One. 2017; 12(1):e0169172. PMC: 5207741. DOI: 10.1371/journal.pone.0169172. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Gevaert O, Echegaray S, Khuong A, Hoang C, Shrager J, Jensen K . Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Sci Rep. 2017; 7:41674. PMC: 5282551. DOI: 10.1038/srep41674. View

13.

Riely G, Pao W, Pham D, Li A, Rizvi N, Venkatraman E . Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006; 12(3 Pt 1):839-44. DOI: 10.1158/1078-0432.CCR-05-1846. View

14.

Schabath M, Massion P, Thompson Z, Eschrich S, Balagurunathan Y, Goldof D . Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One. 2016; 11(8):e0159880. PMC: 4980050. DOI: 10.1371/journal.pone.0159880. View

15.

Tunali I, Stringfield O, Guvenis A, Wang H, Liu Y, Balagurunathan Y . Radial gradient and radial deviation radiomic features from pre-surgical CT scans are associated with survival among lung adenocarcinoma patients. Oncotarget. 2017; 8(56):96013-96026. PMC: 5707077. DOI: 10.18632/oncotarget.21629. View

16.

Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

17.

Bland J, Altman D . Multiple significance tests: the Bonferroni method. BMJ. 1995; 310(6973):170. PMC: 2548561. DOI: 10.1136/bmj.310.6973.170. View

18.

Win T, Miles K, Janes S, Ganeshan B, Shastry M, Endozo R . Tumor heterogeneity and permeability as measured on the CT component of PET/CT predict survival in patients with non-small cell lung cancer. Clin Cancer Res. 2013; 19(13):3591-9. DOI: 10.1158/1078-0432.CCR-12-1307. View

19.

Weiss G, Ganeshan B, Miles K, Campbell D, Cheung P, Frank S . Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic. PLoS One. 2014; 9(7):e100244. PMC: 4079229. DOI: 10.1371/journal.pone.0100244. View

20.

Teng F, Meng X, Kong L, Yu J . Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Lett. 2017; 414:166-173. DOI: 10.1016/j.canlet.2017.11.014. View